Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyverna Therapeutics (KYTX) Depreciation & Amortization (CF) (2023 - 2026)

Kyverna Therapeutics posted quarterly Depreciation & Amortization (CF) of $351000.0 for Q1 2026, down 29.94% year-on-year from $501000.0 in Q1 2025, and down 4.62% on a QoQ basis from $368000.0 in Q4 2025.

Kyverna Therapeutics (KYTX) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $351000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 29.94% year-over-year to $351000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 23.37% YoY), and the FY2025 full-year result was $1.8 million, down 15.66% from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 stood at $351000.0, down from $368000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $563000.0 in Q4 2024 and bottomed at $351000.0 in Q1 2026.
  • The 4-year median for Depreciation & Amortization (CF) is $462000.0 (2023), against an average of $460769.2.
  • The widest annual swing landed in 2024, when Depreciation & Amortization (CF) rose 28.33%; it then tumbled 34.64% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $462000.0 in 2023, then grew by 21.86% to $563000.0 in 2024, then sank by 34.64% to $368000.0 in 2025, then slipped by 4.62% to $351000.0 in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $351000.0 (Q1 2026), $368000.0 (Q4 2025), and $415000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 55.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 123.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 13.55 Mn
10 Kyverna Therapeutics 497.98 Mn 265.03 Mn - 351,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 351,000.00
Mar 31, 2026 351,000.00
Dec 31, 2025 368,000.00
Dec 31, 2025 368,000.00
Sep 30, 2025 415,000.00
Sep 30, 2025 415,000.00
Jun 30, 2025 515,000.00
Jun 30, 2025 515,000.00
Mar 31, 2025 501,000.00
Mar 31, 2025 501,000.00
Dec 31, 2024 563,000.00
Dec 31, 2024 563,000.00
Sep 30, 2024 558,000.00
Sep 30, 2024 558,000.00
Jun 30, 2024 530,000.00
Jun 30, 2024 530,000.00
Mar 31, 2024 482,000.00
Mar 31, 2024 482,000.00
Dec 31, 2023 462,000.00
Dec 31, 2023 462,000.00
Sep 30, 2023 438,000.00
Sep 30, 2023 438,000.00
Jun 30, 2023 413,000.00
Jun 30, 2023 413,000.00
Mar 31, 2023 394,000.00
Mar 31, 2023 394,000.00